Editorial
L-Arginine, Nitric Oxide, and Endothelial Dysfunction Underlying Atherosclerotic Cardiovascular Disease (ASCVD)
2023 Volume 30 Issue 10 Pages 1311-1312
Details
2023 Volume 30 Issue 10 Pages 1311-1312
See article vol. 30: 1364-1375
A growing number of evidence suggests that endothelial dysfunction is associated with cardiovascular events1, 2). Nitric oxide (NO) plays a significant role in the maintenance of vascular endothelial function by inhibiting vasoconstriction, vascular smooth muscle cell proliferation, leukocyte adhesion, and platelet aggregation. As the concept that endothelial dysfunction may be regarded as the integrated risk of the risk factors and serves as a sensitive marker for their functional significance, the development and introduction of novel, cost-effective, noninvasive, and reproducible tests to assess endothelial function may conceivably promote the use of these tests for clinical application and practice1, 2).
L-arginine has received much interest during the past two decades because of its potential effects on whole-body NO production and the augmentation of NO-dependent signaling pathways. L-arginine is a source of nitrogen, which is converted to NO by eNOS (endothelial NO synthase) and is involved in maintaining vascular function. Therefore, decreased L-arginine use can be involved in vascular endothelial damage owing to NO bioavailability. Even with normal L-arginine levels, vascular endothelial dysfunction may occur and is referred to as “arginine paradox”3). The global L-arginine bioavailability ratio (GABR) may be a better predictor of coronary artery disease than L-arginine, but its diagnostic potential has not been examined4). Ishinoda et al. reported that the L-arginine/L-ornithine ratio is a predictor of cardiovascular death in this issue5). L-arginine concentrations are decreased in the acute critical stage6), although L-arginine production is not decreased7), suggesting altered L-arginine metabolism. Sepsis and/or altered cytokine states have been reported to activate cationic amino acid transporter-2 (CAT-2), an inhibitor of L-arginine uptake, and deactivate cationic amino acid transporter-1 (CAT-1)8), an uptaker of L-arginine. This fact may suggest that iNOS (inducible NOS) transport increases and eNOS transport decreases in the acute critical stage, as Ishinoda discussed5). In contrast, in the chronic phase, decreased L-arginine availability may occur. A possible mechanism is an increased arginase activity9) (Fig.1). Arginase activity is involved in the metabolism of L-arginine and L-citrulline to L-ornithine and urea, which is conjugated with eNOS action to convert L-arginine and L-citrulline to NO9, 10), and thus it, in turn, may inhibit the utilization of the conversion of L-arginine to NO by eNOS9, 10). CAT-1 can also suppress the conversion utilization of L-arginine to NO by increasing L-arginine10). The L-arginine/L-ornithine ratio may indicate the condition of the above metabolic derangement involved in these NO production.
CAT-1: cationic amino acid transporter- 1; eNOS: endothelial nitric oxide synthase.
Future studies are required to clarify the following: 1) whether the L-arginine/L-ornithine ratio really indicates the above assumption in the clinical setting of endothelial dysfunction, 2) if so, how this marker can be used as a biomarker of the onset of atheoxclerotic cardiovacular disease.
None.
